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A B S T R A C T
Background
Some observational studies have suggested that people who eat a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or
minerals (selenium and zinc) may be less likely to develop age-related macular degeneration (AMD).
Objectives
The aim of this reviewwas to examine the evidence as to whether or not taking vitamin ormineral supplements prevents the development
of AMD.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (which contains the Cochrane Eyes and Vision Group
Trials Register) in The Cochrane Library (2007, Issue 3), MEDLINE (1966 to August 2007), SIGLE (1980 to 2005/03), EMBASE
(1980 to August 2007), National Research Register (NRR) (2007, Issue 3), AMED (1985 to January 2006) and PubMed (on 24
January 2006 covering last 60 days), reference lists of identified reports and the Science Citation Index. We contacted investigators and
experts in the field for details of unpublished studies.
Selection criteria
We included all randomised trials comparing an antioxidant vitamin and/or mineral supplement (alone or in combination) to control.
We included only studies where supplementation had been given for at least one year.
Data collection and analysis
Both review authors independently extracted data and assessed trial quality. Data were pooled using a fixed-effect model.
Main results
Three randomised controlled trials were included in this review (23,099 people randomised). These trials investigated alpha-tocopherol
and beta-carotene supplements. There was no evidence that antioxidant vitamin supplementation prevented or delayed the onset of
AMD. The pooled risk ratio for any age-related maculopathy (ARM) was 1.04 (95% CI 0.92 to 1.18), for AMD (late ARM) was 1.03
(95% CI 0.74 to 1.43). Similar results were seen when the analyses were restricted to beta-carotene and alpha-tocopherol.
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Authors’ conclusions
There is no evidence to date that the general population should take antioxidant vitamin and mineral supplements to prevent or delay
the onset of AMD. There are several large ongoing trials. People with AMD should see the related Cochrane review “Antioxidant
vitamin and mineral supplements for slowing the progression of age-related macular degeneration” written by the same author.
P L A I N L A N G U A G E S U M M A R Y
Antioxidant vitamins and mineral supplements to prevent the development of age-related macular degeneration
Age-related macular degeneration (AMD) is a condition affecting the central area of the retina (back of the eye). The retina can
deteriorate with age and some people get lesions that can lead to loss of central vision. Some studies have suggested that people who eat
a diet rich in antioxidant vitamins (carotenoids, vitamins C and E) or minerals (selenium and zinc) may be less likely to get AMD. The
authors identified three large, high quality randomised controlled trials based in Australia, Finland and USA which had investigated the
effects of vitamin E and beta-carotene supplementation. This review found no evidence that people in the general population should
take antioxidant vitamin or mineral supplements in order to delay the onset of AMD. The results of ongoing trials are awaited.
B A C K G R O U N D
Introduction
Age-relatedmacular degeneration (AMD) is a disease affecting the
central area of the retina (macula). In the early stages of the dis-
ease lipid material accumulates in deposits underneath the retinal
pigment epithelium. These deposits are known as drusen, and can
be seen as pale yellow spots on the retina. The pigment of the reti-
nal pigment epithelium may become disturbed with areas of hy-
perpigmentation and hypopigmentation. In the later stages of the
disease, the retinal pigment epithelium may atrophy completely.
This loss can occur in small focal areas or can be widespread (ge-
ographic). In some cases, new blood vessels grow under the reti-
nal pigment epithelium and occasionally into the subretinal space
(exudative or neovascular). Haemorrhage can occur which often
results in increased scarring of the retina.
Presentation and diagnosis
The early stages of the disease are in general asymptomatic. In
the later stages there may be considerable distortion of vision and
complete loss of visual function, particularly in the central area of
vision.
Epidemiology
Population-based studies suggest that, in people 75 years andolder,
approximately 30% have early signs of the disease and 7% have
late stage disease (Klein 1992). It is the most common cause of
blindness and visual impairment in industrialised countries. In
the UK for example, over 30,000 people are registered as blind or
partially sighted annually, half of whom have lost their vision due
to macular degeneration (Evans 1996).
Treatment options
Currently there is no treatment which can restore vision in AMD.
Photoreceptors in the retina are subject to oxidative stress through-
out life due to combined exposures to light and oxygen. It has
been proposed that antioxidants may prevent cellular damage in
the retina by reacting with free radicals produced in the process of
light absorption (Christen 1996).
There are a number of non-experimental studies that have exam-
ined the possible association between antioxidant micronutrients
and AMD, although few studies have examined supplementation
specifically (Chong 2007; Evans 2001). Data on vitamin intake
in observational studies should be considered cautiously as peo-
ple who have a diet rich in antioxidant vitamins and minerals or
who choose to take supplements regularly, are different in many
ways from those who do not; these differences may not be ade-
quately controlled by statistical analysis. Inconsistent results have
been found in these observational studies.
2Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rationale for a systematic review
Antioxidant vitamin and mineral supplements are increasingly be-
ing marketed for use in age-related eye disease, including AMD.
The aimof this reviewwas to examine the evidence as towhether or
not taking vitamin or mineral supplements prevents the develop-
ment of AMD. See also the related Cochrane review “Antioxidant
vitamin and mineral supplements for slowing the progression of
AMD” which considers whether supplementation for people with
AMD slows down the progression of the disease (Evans 2006).
O B J E C T I V E S
The objective of this review was to determine whether antioxi-
dant vitamin and/or mineral supplementation prevents the devel-
opment of AMD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised trials comparing antioxidant vitamin
and/ormineral supplementation (alone or in combination) to con-
trol.
Types of participants
Participants in the trials were people in the general population,
with or without diseases other than AMD. We excluded trials in
which the participants were exclusively people with AMD. These
trials are considered in a separate Cochrane review examining the
effect of supplementation on progression of the disease (Evans
2006).
Types of interventions
Antioxidants were defined as any vitamin or mineral which is
known to have antioxidant properties in vivo or which is known
to be an important component of an antioxidant enzyme present
in the retina. We considered the following: vitamin C, vitamin
E, carotenoids, selenium and zinc. We included studies where
supplementation had been given for at least one year.
Types of outcome measures
The following outcomes were used:
(1) number of participants developing AMD;
(2) number of participants with visual loss due to AMD;
(3) quality of life measures;
(4) any adverse outcomes reported.
We used the following definitions:
AMD: this was taken as defined by trial investigators. It is com-
monly defined as: in the macular area 3,000 microns diameter
from fovea: drusen with or without pigmentary abnormalities or
geographic atrophy or characteristic choroidal neovascularisation
with no other cause. Where possible, we have used the ’Inter-
national Classification and Grading System for Age-related Mac-
ulopathy and Age-related Macular Degeneration’ (ARM Study
Group 1995). The group propose an overall term of age-related
maculopathy (ARM) encompassing both early age-relatedmacular
changes (soft drusen >= 63 microns, hyper- and/or hypo-pigmen-
tation) and late stage disease (neovascularisation and geographic
atrophy), observed on grading of colour fundus photographs. The
term AMD is restricted to describe late stage disease.
Visual loss: any well-defined outcome based on visual acuity was
used depending on the way in which authors presented trial data.
Quality of life: any validated measurement scale which aims to
measure the impact of visual function loss on quality of life of
participants.
Search methods for identification of studies
Electronic searches
We searched for trials that tested antioxidant vitamin or min-
eral supplementation. Our initial search did not include terms
for AMD or eye terminology as we planned to contact investiga-
tors of eligible trials to establish whether data on vision outcomes
had been collected. We included eye terminology in subsequent
searches, since no trials were identified in the first phase that had
not included eye terminology. There were no language or date re-
strictions in the searches.
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL) (which contains the Cochrane Eyes and Vision
Group Trials Register) in The Cochrane Library,MEDLINE, EM-
BASE, SIGLE, National Research Register (NRR), PubMed and
Allied&ComplementaryMedicine (AMED). The searches inThe
Cochrane Library, MEDLINE, EMBASE and National Research
Register were last updated on 2 August 2007.
See: Appendices for details of search strategies used for each
database.
Searching other resources
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We searched the Science Citation Index and the reference lists of
reports of trials that were selected for inclusion. We contacted the
investigators of included and excluded trials to ask if they knew of
any other relevant published or unpublished trials.
Data collection and analysis
Selection of trials
Each review author assessed half of the titles and abstracts resulting
from the searches and selected studies according to the definitions
in the ’Criteria for considering studies for this review’. To check
that we were consistent, we both assessed a subset of 100 records
and compared results. We obtained full copies of all reports re-
ferring to controlled trials that definitely or potentially met the
inclusion criteria. We assessed the full copies and selected studies
according to the inclusion criteria. We wrote to authors of trials
for which there were no published outcome data on AMD to ask
whether they had collected any data on eye disease outcomes.
As none of the trials responded positively, i.e. gave us unpublished
data on AMD, for further updates of this review we only consid-
ered trials with published data on AMD.
Assessment of methodological quality
Each author independently assessed the methodological quality of
trials according tomethods set out in the Section 6 of theCochrane
Handbook for Systematic Reviews of Interventions (Higgins 2006).
Only trials that met the inclusion criteria and collected outcome
data on eye diseases were assessed for quality. Five parameters were
considered: allocation concealment, method of allocation to treat-
ment, documentation of exclusions, masking of outcome assess-
ment and completeness of follow-up. Each parameter of trial qual-
ity was graded: A - low risk of bias; B - moderate risk of bias; and
C - high risk of bias. The review authors were not masked to any
trial details. Trials scoring C on allocation concealment, that is,
where allocation was inadequately concealed, were excluded.
Data collection
Both authors independently extracted data on included trials us-
ing a form developed by the Cochrane Eyes and Vision Group
(available from the editorial base). The results were compared and
discrepancies were resolved.
Data synthesis
We summarised data using the risk ratio, after testing for hetero-
geneity between trial results using a standard chi-squared test. We
also planned to conduct sensitivity analyses to determine the im-
pact of study quality on effect size.
R E S U L T S
Description of studies
See:Characteristics of included studies; Characteristics of excluded
studies; Characteristics of ongoing studies.
Results of the search
The initial searches resulted in 3178 titles and abstracts. Of these,
208 were reports of potentially eligible trial reports. From these re-
ports we identified seven primary prevention trials of antioxidant
vitamin or mineral supplements (ATBC 1994; CARET; de Klerk
1998; LINXIAN; Nambour 1995; PHS I; WHS). Investigators
from three trials have confirmed that they did not collect data
on AMD (CARET; de Klerk 1998; Nambour 1995). These trials
have been excluded from the review. We did not receive a response
from one trial (LINXIAN) and this trial has been excluded. Two
trials have published data on AMD outcomes (ATBC 1994; PHS
I) and are included in this review. One ongoing trial is planning to
publish information on AMD (WHS). Search of the National Eye
Institute Clinical Research register identified one further ongo-
ing trial which is collecting information on AMD - the Women’s
Antioxidant Cardiovascular Study (WACS). There are two trials
that have recruited participants with and without AMD (AREDS;
VECAT). VECAT is included in this review because 82% of par-
ticipants did not have signs of ARM. AREDS is not included in
this review because ARM outcomes for people without ARM at
baseline were not reported; it is included in the Cochrane review
examining the effect of supplementation on progression of the
disease (Evans 2006).
The original search strategy involved identifying all trials of an-
tioxidant interventions and asking trialists if they had collected
data on AMD. We wrote to the authors of 60 trials of antioxidant
interventions in people with diseases other than AMD. To date
we have received 15 responses and none has collected any relevant
data. All 60 trials are shown in the excluded studies section of this
review. As this proved to be an inefficient way of identifying rel-
evant trials, subsequent searches included terms for AMD. Three
hundred and sixty seven reports of trials were found in May 2002,
343 in May 2005 and 64 reports in January 2006 but no further
trials were identified that were relevant for inclusion in this re-
view. The results of the PHS I study were published in 2007. The
searches were repeated in August 2007 in which a total of 129
reports of studies were identified.
Included studies
Summary of trial characteristics
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Below is a summary of the three trials included in this review. See
the ’Characteristics of included studies’ Table for more detailed
information.
Types of participants
The studies took place in Australia, USA and Finland. Two studies
recruitedmales only (ATBC1994; PHS I) and one study recruited
men and women (VECAT). People taking part in the trials were
identified from the general population. Participants in PHS I were
male physicians. In ATBC 1994, a random sample of 1035 men
aged 65 years or above from the main study were invited to par-
ticipate with a response rate of 91% (941 men). In VECAT 18%
had ARM at baseline.
Types of intervention
In ATBC 1994, the groups received either alpha-tocopherol 50
mg per day alone, beta-carotene 20 mg per day alone, alpha-
tocopherol and beta-carotene or placebo. All formulations were
coloured with quinoline yellow. Treatment duration was five to
eight years (median 6.1). InVECAT participants were randomised
to vitamin E (500 IU a day) or placebo. Supplementation contin-
ued for four years. In PHS I the groups received aspirin 325 mg
every other day, beta-carotene 50 mg every other day, aspirin and
beta-carotene or placebo. Treatment duration averaged 12 years.
Types of outcome measures
In ATBC 1994, three photographs of each eye were taken with
a Canon fundus camera at 40 and 60 degree angles on Kodak
Ektachrome 100 ASA slide film. These photographs were graded
by one observer masked to the participant’s treatment group. The
following grades of maculopathy were used: 0 = none; I = dry
maculopathy with hard drusen and/or pigmentary changes; II =
soft macular drusen; III = disciform degeneration; IV = geographic
atrophy. These have been recategorised in this review according to
the International Grading System (ARM Study Group 1995) as
follows: early ARM = I and II; late ARM = III and IV; geographic
atrophy = IV; and neovascular AMD = III.
In PHS I AMDwas ascertained by self-report “Have you ever had
macular degeneration diagnosed in your right or left eye?”. If the
participant answered yes to this question permission was gained to
contact their ophthalmologist or optometrist and further details
were obtained from the medical records.
In VECAT, photographs were taken with a Nidek 3-DX fundus
camera on Kodachrome 64 ASA colour film. The photographs
were graded at baseline independently by two trained graders ac-
cording to the International Grading System (ARM Study Group
1995). The primary outcome was ’early AMD-3’. On photo-
graphic grading this was defined as soft drusen (distinct or in-
distinct) or pigmentary changes (hyperpigmentation or hypopig-
mentation). On clinical grading this was large/soft drusen or non-
geographical RPE atrophy. VECAT used Bailey-Lovie Charts #4
and #5 (National Vision Research Institute, Australia).
Excluded studies
See Characteristics of excluded studies table.
Risk of bias in included studies
All three studies were of high quality and scored A - low risk of
bias on all quality parameters. The allocation was concealed by
means of coded tablets and randomly assigned; exclusions were
documented and follow up was equal between the study groups;
outcome assessment was masked to study group and analysis was
intention-to-treat.
Effects of interventions
In ATBC 1994 there were 728 people randomised to any antiox-
idant and 213 to placebo. There was no association of treatment
group with any sign of maculopathy. There were 216 cases of early
ARM or AMD in the antioxidant groups and 53 in the placebo
group (risk ratio (RR) 1.19 95% confidence interval (CI) 0.92 to
1.54). The majority of these cases were early ARM. There were
only 14 cases of late AMD.Of these, four were geographic atrophy
and 10 neovascular disease. There was one case of geographic atro-
phy and no cases of neovascular disease in the placebo group. The
findings are similar when each of the antioxidant groups - alpha-
tocopherol, beta-carotene, alpha-tocopherol and beta-carotene -
are compared with placebo.
In VECAT there were 92/504 in the vitamin E group with ARM
compared to 92/512 in the placebo group (RR 1.02, 95% CI 0.78
to 1.32). The majority of these cases were early ARM. There were
nine cases of late AMD, five in the treatment group and four in
the placebo group.
In PHS I there were 162 cases of ARM causing visual loss of 6/
9 or worse in the beta carotene group vs 170 cases in the placebo
group (RR adjusted for aspirin assignment 0.96, 95% CI 0.78 to
1.20). Secondary end points of ARM with or without vision loss
(275 vs 274 cases, adjusted RR 1.01, 95% CI 0.86 to 1.20) and
advanced ARM (63 vs 66 cases, adjusted RR 0.97, 95% CI 0.69
to 1.37) were reported.
Overall 23,099 participants were randomised in ATBC, VECAT
and PHS I (see Data and analyses 1). There were 583 cases of
ARM in the antioxidant groups and 419 cases of ARM in the
placebo groups (Analysis 1.1). The results of the three studies were
consistent (I2 = 0%). There was little evidence of any effect of
antioxidant supplementation (RR 1.04, 95% CI 0.92 to 1.18).
Similarly with AMD (late ARM) the trials were consistent and
indicate little evidence of any effect of supplementation (RR 1.03,
95% CI 0.74 to 1.43) (Analysis 1.3). There were fewer late ARM
events (81 antioxidant, 71 placebo).
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There was less evidence available comparing alpha-tocopherol
alone versus placebo (see Data and analyses 2). A total of 1466
people randomised in VECAT and ATBC resulted in 167 cases
of ARM in the alpha-tocopherol group and 145 in the placebo
group (Analysis 2.1). The trial results were reasonably consistent
I2 = 18.8%. There was little evidence of any effect of supplemen-
tation with alpha-tocopherol on the incidence of ARM RR 1.11
(95% CI 0.91 to 1.36). There were fewer cases of late ARM - 13
in the alpha-tocopherol groups and five in the placebo (Analysis
2.3). Again there was little evidence of any benefit from supple-
mentation with a pooled RR in the direction of harm 2.51, 95%
CI 0.89 to 7.10.
A total of 21,589 people have been randomised into ATBC and
PHS I comparing beta-carotene with placebo Data and analyses
3). There were 343 cases of ARM in the beta-carotene groups
and 327 in the control groups (Analysis 3.1). The results of the
trials were consistent (I2 = 0%) and did not indicate any benefit
of supplementation (RR = 1.03, 95% CI 0.98 to 1.19). There
were 65 cases of late ARM in the beta-carotene groups and 67
cases of late ARM in the control (Analysis 3.2). Again the results
of the trials were consistent (I2 = 0%) and indicated little effect of
supplementation (RR = 0.97, 95% CI 0.69 to 1.18).
D I S C U S S I O N
This review did not find evidence that supplementation with an-
tioxidant vitamin supplements prevents the development of AMD.
However, the trials included in this review have investigated vi-
tamin E (alpha-tocopherol) and beta-carotene only. There is no
evidence as to the possible benefits and harms of other antioxidant
supplements with respect to the prevention of AMD.
This review includes three reasonably large high quality studies
which have randomised over 23,000 members of the population
to antioxidant supplementation or placebo. Duration of supple-
mentation has ranged from four to 12 years.
In ATBC 1994 there was no association with the treatment group
and development of early stages of the disease. If anything, there
was a tendency for more cases to be present in the treatment rather
than the placebo group. This was not statistically significant. One
drawback of adding-on a maculopathy study to a trial of primary
prevention is that we have no information on maculopathy sta-
tus before supplementation. Therefore we have to assume that (1)
maculopathy was equally distributed across study groups at the
start of the study and (2)most observed events occurred during the
study period. It is likely that this is true for a reasonable propor-
tion of the events as the maculopathy study began eight years after
recruitment for the main trial and randomisation should have en-
sured equal distribution of maculopathy between the two groups.
Supplementation in this study began at age 50 to 69 and lasted five
to eight years. Currently we do not know at what age antioxidant
protectionmay be important. Itmay be that this was too late or too
short a period of supplementation to show an effect. This study
was conducted in Finnishmale smokers andwe have to be cautious
in extrapolating the findings to other geographical areas, to people
in other age-groups, to women and to non-smokers. However, the
incidence of AMD, particularly neovascular disease, is likely to be
higher in smokers (Klein 1993) which means that they provide a
good population to demonstrate any potential protective effects
of antioxidant supplementation. There were no ophthalmological
adverse effects recorded during the study although there was non-
significant increased risk of maculopathy in the treatment groups.
In the main trial it was observed that men who received beta-
carotene had a higher incidence of lung cancer (ATBC1994). This
finding was also observed in CARET (Omenn 1996). It cannot be
assumed that consumption of these supplements is without harm.
The results of VECAT similarly do not provide evidence of a
benefit of supplementation in people with no or mild/borderline
AMD, although again these studies have been underpowered to
examine late-stage disease.
In the PHS I over 20,000 physicians received supplementation
with beta-carotene over 12 years. There was little evidence of any
benefit of beta-carotene supplementation. AMD was ascertained
bymedical record review and thereforemay have been less accurate.
However, there is no reason to suppose that the ascertainment will
have been different in the treatment and control groups.
The Age-Related Eye Disease study is not included in this review.
However, there were 2180 people recruited with no or mild/bor-
derline AMD (AREDS 2001a). The study reported no benefit of
the study treatment for these people however the number of events
was small.
Although the number of people randomised in these studies is
large there is still a degree of uncertainty in the pooled estimates.
In the pooled analyses the risk ratios were largely around the null
value or just above the null value. There were more cases of ARM.
The lower 95% confidence interval for these analyses was around
0.90. This suggests that themost protective effect that these results
are compatible with is of the order of a 10% risk reduction. There
were fewer cases of AMD. In these analyses the lower 95% CI was
around 0.75. This suggests that the maximum protective effect
that these results are compatible with is a 25% risk reduction.
The upper confidence intervals are in the region 1.20 to 1.50
indicating that vitamin supplementation could be associated with
an increased risk of ARM or AMD.
Overall beta-carotene supplementation is unlikely to prevent the
development of AMD in the general population.With the amount
of information available, a protective effect would have been evi-
dent. For vitamin E there are less data available however the risk
ratios are in the direction of harm. For that reason it is unlikely
that vitamin E supplements prevent the development of AMD.
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A recent systematic review of observational prospective studies also
found little evidence of a protective effect of dietary antioxidants
(Chong 2007). The only dietary antioxidant for which a reduction
was seen was vitamin E, in contrast to the evidence from the
trials included in this review. It is possible that natural vitamin E
fromdietary sources rather than artificial supplements has different
effects, or alternatively high levels of dietary vitamin E might be a
marker for other nutrients, for example, dietary fatty acids.
We are awaiting the results of several large ongoing studies in the
USA and Australia. In the Women’s Health Study 39,876 women
were randomised using a 2x2 factorial design to low-dose aspirin
and vitamin E (WHS). There is now a further Physicians Health
Study (PHS II). In theWomen’s AntioxidantCardiovascular Study
8171 female health professionals who are at high risk for cardiovas-
cular disease morbidity and mortality are being randomised using
a 2x2x2x2 factorial design to vitamin C, vitamin E, folate, vitamin
B6 and vitamin B12 supplementation (WACS).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
There is no evidence from randomised trials that healthy people
should take antioxidant vitamin and mineral supplements to pre-
vent or delay the onset of AMD.
Implications for research
There are a number of unanswered questions in the prevention of
AMD. The hypothesis that antioxidant micronutrients may pro-
tect against the disease is a reasonable one. We do not know at
what stage the protective effect may be important, nor the poten-
tial interactions with genetic effects and other risk factors for the
disease such as smoking. The research to date shows that we can-
not extrapolate to taking vitamin supplements without good evi-
dence of their effectiveness and safety. Further trials are warranted
to address this question and the results of several large ongoing
trials are awaited. The small number of incident events in healthy
people mean that trials need to be very large. Four large primary
and secondary prevention trials in the field of cancer and cardio-
vascular disease have added-on an examination of eye disease. This
would seem to be a cost-effective way forward in research in this
area.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
ATBC
Methods Method of allocation: random. Sponsor provided coded capsules.
Masking: participant: yes; provider: yes; outcome: yes.
Exclusions after randomisation: no.
Losses to follow up: 31%. Random sample for maculopathy study: 9%.
Unusual study design: 2x2 factorial design. Maculopathy add-on random sample in 2 regions
Participants Country: Finland.
Number of participants randomised: 29,133. Random sample of 1035 selected for maculopathy study.
Age: 50 to 69 years in 1984. Maculopathy study 1992/3 in people aged 65 plus.
Sex: Male.
Inclusion criteria: 5 or more cigarettes daily.
Exclusion criteria: history of cancer or serious disease limiting ability to participate; those taking supple-
ments vitamine E, A or betacarotene in excess of predefined doses; those treated with anticoagulants
Interventions Treatment: 3 regimens: alpha-tocopherol (50 mg), betacarotene (20 mg) or alpha-tocopherol and betac-
arotene.
Control: placebo.
Duration: 5 to 8 years (median 6.1).
Outcomes ARM: Four grades:
Grade I: Dry maculopathy with hard drusen and/or pigmentary changes.
Grade II: Soft macular drusen.
Grade III: Disciform degeneration.
Grade IV: Geographic atrophy.
Notes Compliance with treatment excellent; 4/5 active participants took more than 95% of sceduled capsules.
Drop-out rate and compliance similar between all four groups
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
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PHS I
Methods Method of allocation:
Coded tablets.
Masking:
Participant: Yes
Provider: Yes
Outcome: Yes
Exclusions after
randomisation:
Losses to follow-up:
Unusual study design:
Two by two factorial design.
Participants Country: USA
Number randomised: Originally 22,071 men were randomised: 11,036 to beta-carotene
11,035 to beta-carotene placebo.
21,142 participants were followed up for at least 7 years and provided information on diagnoses of ARM
made during the first 7 years of the trial.
10,585 were in the beta carotene group and 10,557 were in the placebo group.
Age: 40 to 84 years in 1982
Sex: Male
Inclusion criteria:
Physician aged 40 to 84 years in 1982 with no history of cancer, myocardial infarction, stroke or transient
cerebral ischaemia.
Exclusion criteria:
Interventions Treatment:
Four groups:
1.Aspirin 325mg every other day plus beta-carotene placebo.
2.Beta-carotene 50 mg every other day plus aspirin placebo.
3.Both active agents
Control:
4.Both placebos
Duration:
Aspirin component terminated early January 1988
Beta carotene component terminated Dec 1995. Mean duration 12 years range (11.6 to 14.2 years)
Outcomes Self-report of AMD followed by medical record review and questionnaire to relevant ophthalmologist.
Primary endpoint: visually significant ARM, defined as a self-report confirmed by medical record evidence
of an initial diagnosis after randomisation but before December 31st 1995 with a reduction in best-
corrected visual acuity to 20/30 or worse attributable to ARM.
Secondary endpoints: ARM with or without vision loss, composed of all incidence cases
Advanced ARM, encompassed of cases of visually significant ARM with pathological signs of disciform
scar, RPE detachment, geographic atrophy, or subretinal neovascular membrane
Notes
Risk of bias
Item Authors’ judgement Description
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PHS I (Continued)
Allocation concealment? Yes A - Adequate
VECAT
Methods Method of allocation: coded bottles.
Masking: participant: yes; provider: yes; outcome: yes.
Losses to follow up: not known.
Participants Country: Australia.
Number of participants randomised: 1204.
Age: 55 to 80 years, mean 66.
Sex: 56% female.
Inclusion criteria: lens and retina of at least one eye available for documentation.
Exclusion criteria: previous cataract surgery or advanced cataract in both eyes; steroid or anticoagulation
use; serious disease; regular use or sensitivity to vitamin E
Interventions Vitamin E 500 IU per day: natural vitamin E in soybean oil medium.
Control: placebo identical in sight, taste and smell.
Duration: 4 years.
Outcomes 2m logMAR visual acuity; clinical examination; colour stereoscopic fundus photographs graded using
International Grading Scheme
Notes Worse eye used as the study eye.
Methodology published but results available from abstract only
Risk of bias
Item Authors’ judgement Description
Allocation concealment? Yes A - Adequate
AMD: Age-related macular degeneration
ARM: Age-related maculopathy
ETDRS: Early Treatment Diabetic Retinopathy Study
IU: International units
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Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
ADSC No published data on age-related macular degeneration. No response from author
Andrews 1969 No published data on age-related macular degeneration. Unable to contact author
AREDS Age-related maculopathy outcomes for people without age-related maculopathy at baseline were not reported
Benner 1994 No published data on age-related macular degeneration. No response from author
Benton 1995 No data on age-related macular degeneration collected.
Blok 1997 No data on age-related macular degeneration collected.
Bogden 1990 No published data on age-related macular degeneration. No response from author
Brewer 1997 No published data on age-related macular degeneration. No response from author
Brown 1998 No published data on age-related macular degeneration. No response from author
Bussey 1982 No published data on age-related macular degeneration. No response from author
Caligiuri 1997 No published data on age-related macular degeneration. No response from author
CARET No data on age-related macular degeneration collected.
CCSG No published data on age-related macular degeneration. No response from author
Chandra 1992 No published data on age-related macular degeneration. No response from author
CHAOS No data on age-related macular degeneration collected.
Clausen 1989 No published data on age-related macular degeneration. No response from author
Constans 1996 No published data on age-related macular degeneration. No response from author
Constantino 1988 No data on age-related macular degeneration collected.
Cucinotta 1994 No published data on age-related macular degeneration. No response from author
DATATOP No published data on age-related macular degeneration. Unable to contact author
de Klerk 1998 No data on age-related macular degeneration collected.
DeCosse 1989 No published data on age-related macular degeneration. No response from author
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(Continued)
Dobson 1984 No data on age-related macular degeneration collected.
ECP-IM No published data on age-related macular degeneration. No response from author
EUROSCAN No published data on age-related macular degeneration. No response from author
Fairley 1996 No published data on age-related macular degeneration. No response from author
Fontham 1995 No data on age-related macular degeneration collected.
Galan 1997 No published data on age-related macular degeneration. No response from author
Garawal 1995 No published data on age-related macular degeneration. No response from author
GISSI No published data on age-related macular degeneration. No response from author
HOPE No data on age-related macular degeneration collected.
Johnson 1997 No published data on age-related macular degeneration. No response from author
Jyothirmayi 1996 No published data on age-related macular degeneration. No response from author
Kuklinski 1994 No published data on age-related macular degeneration. No response from author
Leng 1997 No published data on age-related macular degeneration. Unable to contact author
Li 1992 No published data on age-related macular degeneration. No response from author
LINXIAN No published data on age-related macular degeneration. No response from author
Mayne 1998 No data on age-related macular degeneration collected.
McKeown 1988 No data on age-related macular degeneration collected.
Meyskens 1994 No published data on age-related macular degeneration. No response from author
Munoz 1987 No published data on age-related macular degeneration. No response from author
Munoz 1996 No published data on age-related macular degeneration. No response from author
Nambour 1995 No follow-up data on age-related macular degeneration collected
NPCSG No published data on age-related macular degeneration. No response from author
Pastorino 1991 No published data on age-related macular degeneration. No response from author
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(Continued)
Peng 1993 No published data on age-related macular degeneration. No response from author
PPP No published data on age-related macular degeneration. No response from author
PPSG No data on age-related macular degeneration collected.
Prasad 1995 No published data on age-related macular degeneration. No response from author
Qidong 1997 No published data on age-related macular degeneration. No response from author
REACT No published data on age-related macular degeneration. No response from author
Recchia 1995 No published data on age-related macular degeneration. No response from author
Ret Pig 1993 No published data on age-related macular degeneration. No response from author
SCPS 1989 No data on age-related macular degeneration collected.
SECURE No published data on age-related macular degeneration. No response from author
Shandong 1998 No data on age-related macular degeneration collected.
Sharma 1989 No published data on age-related macular degeneration. No response from author
Steiner 1995 No published data on age-related macular degeneration. No response from author
SUVIMAX No published data on age-related macular degeneration. No response from author
SWSCPSG No data on age-related macular degeneration collected.
Takamatsu 1995 No published data on age-related macular degeneration. No response from author
Tomeo 1995 No published data on age-related macular degeneration. No response from author
Tsubono 1997 No data on age-related macular degeneration collected.
Wahlqvist 1994 No data on age-related macular degeneration collected.
Wright 1985 No published data on age-related macular degeneration. No response from author
YUNNAN No published data on age-related macular degeneration. No response from author
Zaridze 1993 No published data on age-related macular degeneration. No response from author
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Characteristics of ongoing studies [ordered by study ID]
PHS II
Trial name or title Physician’s Health Study II
Methods
Participants 15,000 physicians aged 55 or older
Interventions 2x2x2x2 factorial design
- alternate day betacarotene, alternate day vitamin E, daily vitamin C and a daily multivitamin
Outcomes Age-related macular degeneration: reported diagnosis followed-up by contact with treating ophthalmologist/
optometrist
Starting date
Contact information
Notes
WACS
Trial name or title Women’s Antioxidant Cardiovascular Study
Methods
Participants 8171 female health professionals aged 40 plus with pre-existing cardiovascular disease (CVD) or high risk for
developing CVD
Interventions 2x2x2x2 factorial design
- vitamin E (600 IU on alternate days)
- vitamin C (500 mg daily),
- betacarotene (50 mg on alternate days)
- combination of folate (800 mg daily), vitamin B6 (25 mg daily) and vitamin B12 (1 mg daily)
Outcomes Self report and review of medical records
Starting date 1993
Contact information
Notes
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WHS
Trial name or title Women’s Health Study
Methods
Participants 39,876 women health professionals aged 45 plus
Interventions Low dose aspirin (100 mg on alternate days) and vitamin E (600 IU on alternate days)
Outcomes Self report and review of medical records
Starting date 1992
Contact information
Notes
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D A T A A N D A N A L Y S E S
Comparison 1. ANY ANTIOXIDANT VERSUS PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any ARM 3 23099 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.92, 1.18]
2 Early ARM 2 1957 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.89, 1.29]
3 Late ARM 3 23099 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.74, 1.43]
Comparison 2. ALPHA-TOCOPHEROL VERSUS PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any ARM 2 1466 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.91, 1.36]
2 Early ARM 2 1466 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.87, 1.30]
3 Late ARM 2 1466 Risk Ratio (M-H, Fixed, 95% CI) 2.51 [0.89, 7.10]
Comparison 3. BETA-CAROTENE VERSUS PLACEBO
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Any ARM 2 21589 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.89, 1.19]
2 Early ARM 1 447 Risk Ratio (M-H, Fixed, 95% CI) 1.16 [0.85, 1.58]
3 Late ARM 2 21589 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.69, 1.36]
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Analysis 1.1. Comparison 1 ANY ANTIOXIDANT VERSUS PLACEBO, Outcome 1 Any ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 ANY ANTIOXIDANT VERSUS PLACEBO
Outcome: 1 Any ARM
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 216/728 53/213 18.3 % 1.19 [ 0.92, 1.54 ]
PHS I 275/10585 274/10557 61.3 % 1.00 [ 0.85, 1.18 ]
VECAT 92/504 92/512 20.4 % 1.02 [ 0.78, 1.32 ]
Total (95% CI) 11817 11282 100.0 % 1.04 [ 0.92, 1.18 ]
Total events: 583 (Antioxidant), 419 (Placebo)
Heterogeneity: Chi2 = 1.31, df = 2 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 0.61 (P = 0.54)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 1.2. Comparison 1 ANY ANTIOXIDANT VERSUS PLACEBO, Outcome 2 Early ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 ANY ANTIOXIDANT VERSUS PLACEBO
Outcome: 2 Early ARM
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 203/728 52/213 48.0 % 1.14 [ 0.88, 1.49 ]
VECAT 87/504 88/512 52.0 % 1.00 [ 0.77, 1.32 ]
Total (95% CI) 1232 725 100.0 % 1.07 [ 0.89, 1.29 ]
Total events: 290 (Antioxidant), 140 (Placebo)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.71 (P = 0.48)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 1.3. Comparison 1 ANY ANTIOXIDANT VERSUS PLACEBO, Outcome 3 Late ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 1 ANY ANTIOXIDANT VERSUS PLACEBO
Outcome: 3 Late ARM
Study or subgroup Antioxidant Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 13/728 1/213 2.2 % 3.80 [ 0.50, 28.91 ]
PHS I 63/10585 66/10557 92.3 % 0.95 [ 0.67, 1.34 ]
VECAT 5/504 4/512 5.5 % 1.27 [ 0.34, 4.70 ]
Total (95% CI) 11817 11282 100.0 % 1.03 [ 0.74, 1.43 ]
Total events: 81 (Antioxidant), 71 (Placebo)
Heterogeneity: Chi2 = 1.90, df = 2 (P = 0.39); I2 =0.0%
Test for overall effect: Z = 0.18 (P = 0.85)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.1. Comparison 2 ALPHA-TOCOPHEROL VERSUS PLACEBO, Outcome 1 Any ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 ALPHA-TOCOPHEROL VERSUS PLACEBO
Outcome: 1 Any ARM
Study or subgroup Alpha-tocopherol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 75/237 53/213 38.0 % 1.27 [ 0.94, 1.72 ]
VECAT 92/504 92/512 62.0 % 1.02 [ 0.78, 1.32 ]
Total (95% CI) 741 725 100.0 % 1.11 [ 0.91, 1.36 ]
Total events: 167 (Alpha-tocopherol), 145 (Placebo)
Heterogeneity: Chi2 = 1.23, df = 1 (P = 0.27); I2 =19%
Test for overall effect: Z = 1.07 (P = 0.29)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 2.2. Comparison 2 ALPHA-TOCOPHEROL VERSUS PLACEBO, Outcome 2 Early ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 ALPHA-TOCOPHEROL VERSUS PLACEBO
Outcome: 2 Early ARM
Study or subgroup Alpha-tocopherol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 67/237 52/213 38.6 % 1.16 [ 0.85, 1.58 ]
VECAT 87/504 88/512 61.4 % 1.00 [ 0.77, 1.32 ]
Total (95% CI) 741 725 100.0 % 1.06 [ 0.87, 1.30 ]
Total events: 154 (Alpha-tocopherol), 140 (Placebo)
Heterogeneity: Chi2 = 0.46, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 0.59 (P = 0.55)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 2.3. Comparison 2 ALPHA-TOCOPHEROL VERSUS PLACEBO, Outcome 3 Late ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 2 ALPHA-TOCOPHEROL VERSUS PLACEBO
Outcome: 3 Late ARM
Study or subgroup Alpha-tocopherol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 8/237 1/213 21.0 % 7.19 [ 0.91, 57.01 ]
VECAT 5/504 4/512 79.0 % 1.27 [ 0.34, 4.70 ]
Total (95% CI) 741 725 100.0 % 2.51 [ 0.89, 7.10 ]
Total events: 13 (Alpha-tocopherol), 5 (Placebo)
Heterogeneity: Chi2 = 2.03, df = 1 (P = 0.15); I2 =51%
Test for overall effect: Z = 1.74 (P = 0.083)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
26Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration (Review)
Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 3.1. Comparison 3 BETA-CAROTENE VERSUS PLACEBO, Outcome 1 Any ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 BETA-CAROTENE VERSUS PLACEBO
Outcome: 1 Any ARM
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 68/234 53/213 16.8 % 1.17 [ 0.86, 1.59 ]
PHS I 275/10585 274/10557 83.2 % 1.00 [ 0.85, 1.18 ]
Total (95% CI) 10819 10770 100.0 % 1.03 [ 0.89, 1.19 ]
Total events: 343 (Beta-carotene), 327 (Placebo)
Heterogeneity: Chi2 = 0.76, df = 1 (P = 0.38); I2 =0.0%
Test for overall effect: Z = 0.38 (P = 0.70)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
Analysis 3.2. Comparison 3 BETA-CAROTENE VERSUS PLACEBO, Outcome 2 Early ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 BETA-CAROTENE VERSUS PLACEBO
Outcome: 2 Early ARM
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 66/234 52/213 100.0 % 1.16 [ 0.85, 1.58 ]
Total (95% CI) 234 213 100.0 % 1.16 [ 0.85, 1.58 ]
Total events: 66 (Beta-carotene), 52 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.91 (P = 0.37)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
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Analysis 3.3. Comparison 3 BETA-CAROTENE VERSUS PLACEBO, Outcome 3 Late ARM.
Review: Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration
Comparison: 3 BETA-CAROTENE VERSUS PLACEBO
Outcome: 3 Late ARM
Study or subgroup Beta-carotene Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
ATBC 2/234 1/213 1.6 % 1.82 [ 0.17, 19.93 ]
PHS I 63/10585 66/10557 98.4 % 0.95 [ 0.67, 1.34 ]
Total (95% CI) 10819 10770 100.0 % 0.97 [ 0.69, 1.36 ]
Total events: 65 (Beta-carotene), 67 (Placebo)
Heterogeneity: Chi2 = 0.28, df = 1 (P = 0.60); I2 =0.0%
Test for overall effect: Z = 0.20 (P = 0.84)
0.1 0.2 0.5 1 2 5 10
Favours treatment Favours control
A P P E N D I C E S
Appendix 1. CENTRAL and NRR search strategies used for Issue 3, 2007
#1 MeSH descriptor Macular Degeneration
#2 MeSH descriptor Retinal Degeneration
#3 MeSH descriptor Retinal Neovascularization
#4 MeSH descriptor Choroidal Neovascularization
#5 MeSH descriptor Macula Lutea
#6 macula* near lutea*
#7 ((macul* OR retina* OR choroid*:TI) AND (degener* OR neovasc*:TI))
#8 ((macul* OR retina* OR choroid*:AB) AND (degener* OR neovasc*:AB))
#9 maculopath*
#10 (#1 OR #2 OR #3 OR #4 OR #5 OR #6 OR #7 OR #8 OR #9)
#11 MeSH descriptor Vitamins
#12 vitamin*
#13 MeSH descriptor Vitamin A
#14 retinol*
#15 MeSH descriptor beta Carotene
#16 caroten*
#17 MeSH descriptor Ascorbic Acid
#18 ascorbic next acid
#19 MeSH descriptor Vitamin E
#20 MeSH descriptor alpha-Tocopherol
#21 alpha tocopherol*
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#22 MeSH descriptor Vitamin B 12
#23 cobalamin*
#24 MeSH descriptor Antioxidants
#25 antioxidant* or anti oxidant*
#26 MeSH descriptor Carotenoids
#27 carotenoid*
#28 MeSH descriptor Zinc
#29 zinc*
#30 MeSH descriptor Riboflavin
#31 riboflavin*
#32 MeSH descriptor Selenium
#33 selenium*
#34 MeSH descriptor Lutein
#35 lutein*
#36 MeSH descriptor Xanthophylls
#37 xanthophyll*
#38 zeaxanthin*
#39 (#11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24)
#40 (#25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38)
#41 (#39 OR #40)
#42 (#10 AND #41)
Appendix 2. MEDLINE search strategy used on OVID up to August 2007
1. exp clinical trial/ [publication type]
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp macular degeneration/
14. exp retinal degeneration/
15. exp retinal neovascularization/
16. exp choroidal neovascularization/
17. exp macula lutea/
18. maculopath$.tw.
19. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
20. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
21. (macula$ adj2 lutea).tw.
22. or/13-21
23. exp vitamins/
24. exp vitamin A/
25. vitamin A.tw.
26. retinol$.tw.
27. exp beta carotene/
28. caroten$.tw.
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29. exp ascorbic acid/
30. ascorbic acid$.tw.
31. vitamin C.tw.
32. exp Vitamin E/
33. exp alpha tocopherol/
34. alpha?tocopherol$.tw.
35. alpha tocopherol$.tw.
36. vitamin E.tw.
37. exp Vitamin B12/
38. vitamin B12.tw.
39. cobalamin$.tw.
40. exp antioxidants/
41. ((antioxidant$ or anti) adj1 oxidant$).tw.
42. exp carotenoids/
43. carotenoid$.tw.
44. exp zinc/
45. zinc$.tw.
46. exp riboflavin/
47. riboflavin$.tw.
48. exp selenium/
49. selenium$.tw.
50. exp lutein/
51. lutein$.tw.
52. exp xanthophylls/
53. xanthophyll.tw.
54. zeaxanthin$.tw.
55. or/23-54
56. 22 and 55
57. 12 and 56
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville (Glanville 2006).
Appendix 3. EMBASE search strategy used on OVID up to August 2007
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
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20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. exp retina macula degeneration/
34. exp retina degeneration/
35. exp retina neovascularization/
36. exp subretinal neovascularization/
37. maculopath$.tw.
38. ((macul$ or retina$ or choroid$) adj3 degener$).tw.
39. ((macul$ or retina$ or choroid$) adj3 neovasc$).tw.
40. exp retina macula lutea/
41. (macula$ adj2 lutea$).tw.
42. or/33-41
43. exp vitamins/
44. exp Retinol/
45. vitamin A.tw.
46. retinol$.tw.
47. exp beta carotene/
48. caroten$.tw.
49. exp ascorbic acid/
50. ascorbic acid$.tw.
51. vitamin C.tw.
52. exp alpha tocopherol/
53. alpha?tocopherol$.tw.
54. alpha tocopherol$.tw.
55. vitamin E.tw.
56. vitamin B12.tw.
57. exp cyanocobalamin/
58. cobalamin$.tw.
59. exp antioxidants/
60. ((antioxidant$ or anti) adj1 oxidant$).tw.
61. exp carotenoid/
62. exp zinc/
63. zinc$.tw.
64. exp riboflavin/
65. riboflavin$.tw.
66. exp selenium/
67. selenium$.tw.
68. exp zeaxanthin/
69. zeaxanthin$.tw.
70. lutein$.tw.
71. xanthophyll.tw.
72. or/43-71
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73. 42 and 72
74. 32 and 73
Appendix 4. SIGLE search strategy used up to 2005/03
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
Appendix 5. PubMed search strategy used to 24 January 2006 (last 60 days)
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
Appendix 6. Allied & Complementary Medicine search strategy used up to January 2006
#1 anti-oxidant* or antioxidant* or vitamin* or caroten*
#2 (beta next epsilon next caroten*) or beta-epsilon-caroten* or (alpha next tocopherol) or alpha-tocopherol or selenium or lutein* or
zeaxanthin*
#3 (ascorbic next acid) or caroten* or beta-caroten* or betacaroten*
#4 #1 or #2 or #3
#5 macula* next lutea*
#6 (macul* or retina* or choroid*) and (degener* or neovasc*)
#7 AMD or maculopath*
#8 #5 or #6 or #7
#9 #4 and #8
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presented in the review “Antioxidants for slowing down
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Medical Subject Headings (MeSH)
∗Dietary Supplements; Antioxidants [∗administration & dosage]; Macular Degeneration [∗prevention & control]; Minerals
[∗administration & dosage]; Randomized Controlled Trials as Topic; Vitamins [∗administration & dosage]; alpha-Tocopherol [admin-
istration & dosage]; beta Carotene [administration & dosage]
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Humans
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